Filler

How to remember biological therapeutics

BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e3010 (Published 18 May 2012) Cite this as: BMJ 2012;344:e3010
  1. Neil Samuel Nyholm Graham, foundation year 1 doctor, Guy’s and St Thomas’ NHS Foundation Trust, London
  1. ngraham{at}gmail.com

Some will be aware that the ever expanding repertoire of monoclonal antibody drugs benefits from systematic naming rules, but for those who are not, there is hope: we can understand the non-proprietary names of these drugs, even if we can’t afford to give them to our patients.

Drug names such as “infliximab” are built of four components: [unique naming part] + [target] + [type] + [“mab”].1

Let’s start at the end. What is it? A monoclonal …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe